

Daptomycin

Form:	350mg or 500mg dry powder vial
Reconstitution:	<p>Reconstitute 350mg vial with 7ml or 500mg vial with 10ml sodium chloride 0.9% to give a final concentration of 50mg per 1ml.</p> <p>Inject the diluent slowly down the side of the vial. Rotate the vial to completely wet the powder and allow to stand for 10 minutes. Gently swirl the vial for a few minutes to obtain a clear reconstituted solution. Do not shake as this will cause foaming of the product.</p>
Administration Method:	<p><u>IV Injection</u> After reconstitution, give by slow IV injection over 2 minutes.</p> <p><u>IV Infusion</u> After reconstitution, dilute with 50ml compatible fluid. Infuse over 30 minutes.</p>
Extravasation	Extravasation is likely to cause tissue damage due to low pH.
Compatibility & Stability:	Sodium chloride 0.9% ONLY
Special Notes:	<ul style="list-style-type: none"> • The reconstituted solution ranges in colour from pale yellow to light brown. • Store vials in fridge. • Cases of interference between daptomycin and a reagent used in some assays of prothrombin time (PT) and INR have led to an in-vitro prolongation of PT and elevation of INR. To minimise this risk, PT or INR samples should be taken immediately prior to the time of the daptomycin dose. • Creatinine phosphokinase (CPK) should be monitored at baseline and at least once weekly during therapy (more frequently if GFR less than 30ml/min). Any patient that develops unexplained muscle pain, tenderness, weakness or cramps should have CPK levels monitored every 2 days. • This is a RESTRICTED antimicrobial – see CUH Antimicrobial Guidelines or NCHD.ie app for further information.

Information provided relates to Cubicin® manufactured by MSD.

This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542